Navigation Links
Treatment Combo for Pancreatic Cancer Has Limited Benefit
Date:3/4/2008

Chemo/chemoradiation therapy extended survival but not significantly

TUESDAY, March 4 (HealthDay News) -- In patients who had surgery for pancreatic cancer, adding the chemotherapy drug gemcitabine to chemoradiation prolonged survival, but the improvement was not statistically significant, a new study finds.

Among patients who have surgery to remove pancreatic cancer, there is a 50 percent to 85 percent rate of local relapse and a five-year survival rate of less than 20 percent, according to background information in the study.

This makes the combination of added postoperative chemotherapy and radiation an important consideration. Previous research has shown that gemcitabine is more effective than the drug fluorouracil at improving patient outcomes.

This study examined whether the addition of gemcitabine to the supplemental treatment of fluorouracil chemoradiation improved survival in patients who had a portion of their pancreas removed as a treatment for pancreatic cancer.

During the study, the 451 patients received either chemotherapy with gemcitabine (221) or with fluorouracil (230) for three weeks prior to chemoradiation therapy and for 12 weeks after chemoradiation therapy (with fluorouracil).

Among the 388 patients with pancreatic head tumors, those in the gemcitabine group had a median (midpoint) survival of 20.5 months and a three-year survival rate of 31 percent, compared to 16.9 months and 22 percent among those in the fluorouracil group. The rates of certain level (grade 4) of hematologic (abnormalities in blood cell counts) toxicity were 1 percent in the fluorouracil group and 14 percent in the gemcitabine group.

There were no differences in neutropenia (a blood disorder), infection, or in the ability to complete chemotherapy or radiation therapy.

"The addition of gemcitabine to (supplemental) fluorouracil-based chemoradiation was associated with a survival benefit for patients with resected pancreatic cancer, although this improvement was not statistically significant," the study authors concluded.

The study was published in the March 5 issue of the Journal of the American Medical Association.

More information

The American Cancer Society has more about pancreatic cancer.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, March 4, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New potential drug target for the treatment of atherosclerosis
2. New Treatment for Lazy Eye Shows Promise
3. New target for cancer therapy may improve treatment for solid tumors
4. ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old
5. Customized treatments for sepsis lower treatment time and reduce length of ICU stays
6. FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
7. Geriatric Oncology Consortium (GOC) Announces Tampa Bay Road Rally to Raise Awareness for the Treatment of Seniors With Cancer
8. Comparison of antipsychotic treatments in adolescents with schizophrenia
9. Treatment for disease that affects estimated 1 in 2000 children gets them to eat again
10. FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old
11. Biomarkers for Mood May Alter Psychiatric Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2019)... ... 20, 2019 , ... cbdMD, a Level Brands company (NYSE ... , Mingo Rad dedicates its resources to offering superior CBD packed with ... manufacturing process, Mingo Rad offers as non-GMO, gluten- and THC-free broad-spectrum product. Mingo ...
(Date:3/20/2019)... ... 2019 , ... Adam Equipment, a leading provider of professional balances worldwide, will ... 26-28 March at Paris expo Porte de Versailles in France. , During the show, ... of balances. Both balance lines include models that deliver two to five places of ...
(Date:3/19/2019)... ... March 19, 2019 , ... The US HealthConnect group of CME companies ... expert William Mencia, M.D., FACEHP, CHCP. Dr. Mencia will serve as Vice President ... Education , Medtelligence , and AGILE . , “William’s expertise ranks at ...
(Date:3/19/2019)... ... March 19, 2019 , ... Healthy Hemp Oil, a ... attitudes surrounding cannabis and its usage, as well as potential changes to those ... about marijuana given recent legislation, views on the effects of cannabis and ...
(Date:3/19/2019)... ... March 19, 2019 , ... Warner Pacific is excited ... time and provides them with even more convenience. , The Warner Pacific App now ... brokers can quickly and conveniently give their clients key information on premium costs, deductibles ...
Breaking Medicine News(10 mins):
(Date:3/17/2019)... ... 2019 , ... The arthroscopic superior capsule reconstruction (SCR) surgical ... opportunity to return to sports and physically-demanding work, according to research presented today ... which examined patient outcomes up to five years after surgery, built upon earlier ...
(Date:3/16/2019)... ... ... Oral surgeons in West Hartford and Manchester, CT, Drs. Joel ... Implant Synergy Boot Camp. The first course of this dental implant continuing education series ... understand the placement of and newest breakthroughs in full arch dental implants solutions. , ...
(Date:3/15/2019)... ... March 15, 2019 , ... ... as one of the best plastic surgeons in the country by Castle Connolly's ... find the best healthcare professionals in acknowledged medical specialties such as plastic surgery, ...
Breaking Medicine Technology: